Abstract
d-α-Tocopheryl polyethylene glycol 1000 succinate (TPGS) has been widely used in a variety of oral applications to enhance dissolution, solubility, and/or bioavailability of poorly-water soluble drugs. In addition, the use of TPGS could potentially minimize achlorhydric effects typically existing in patients co-administered with proton pump inhibitors (PPI) or H2 receptor blockers. The incorporation of TPGS in tablets, however, can have undesirable effects on compaction, physical stability, and processing. Therefore, the goal of this study was to develop a systematic approach using high-shear wet granulation (HSWG) to effectively incorporate TPGS into solid oral formulations to enhance bioavailability under achlorhydric conditions without tablet defects. TPGS levels were optimized and defined based on dissolution, bioperformance, physical stability, and tablet properties. TPGS-containing HSWG formulations had significantly improved processing and flow properties and outperformed dry granulation formulations in dissolution and bioperformance under achlorhydric conditions. Furthermore, the formulation robustness of the HSWG formulations was demonstrated through similar dissolution profiles despite containing different attributes of a poorly water-soluble drug. Therefore, HSWG formulations with the addition of TPGS can be used to minimize not only achlorhydric effects but also the sensitivity of dissolution against variable attributes of a poorly water-soluble drug.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.